О ситуации с заболеваемостью гемофильной инфекцией в некоторых странах регионов ВОЗ

Актуальность. Коэффициент летальности при Haemophilus influenzae серотип b может достигать 5% даже при соответствующем лечении. До 40% детей, перенесших инфекцию, могут всю жизнь страдать от осложнений. Несмотря на то, что с внедрением вакцинации заболеваемость H. influenzae тип b снизилась в последние три десятилетия, ситуация с этой инфекцией должна находится под контролем, в частности потому, что она во всех регионах мира благополучна и есть вероятность вытеснения серотипа b другими патегенными штаммами. В этой в связи оценка эпидемической ситуации по H. influenzae тип b является весьма актуальной.
Цель. Оценить заболеваемость гемофильной инфекцией типа b в отдельных странах мира и Российской Федерации на фоне внедрения вакцинопрофилактики.
Заключение. Заболеваемость инвазивной Hib-инфекцией в странах, где вакцинация против этой инфекции была включена в национальные программы иммунизации зависит от поддержания высокого уровня охвата прививками. Устойчиво низкая заболеваемость во всех странах, которые внедрили вакцину против Hib-инфекции, иллюстрирует успешность программ плановой вакцинации, обеспечивающих эффективную защиту вакцинированных и способствующих формированию коллективного иммунитета. Однако продолжающееся выявление случаев инвазивных форм гемофильной инфекции вызывает опасение, что при проведении в мире массовой иммунизации возможно вытеснение серотипа b другими патогенными серотипами.

1. Pinkbook: Haemophilus influenzae (Hib). 2022. Доступно на: https://www.cdc.gov/vaccines/pubs/pinkbook/hib.h23).

2. Zarei, A., Almehdar, HA., Redwan, E.M. Hib Vaccines: Past, Present, and Future Perspectives. J. Immunol. Res. 2016, 7203587, doi:10.1155/2016/7203587.

3. Peltola, H. Worldwide Haemophilus influenzae type b Disease at the Beginning of the 21st Century: Global Analysis of the Disease Burden 25 Years after the Use of the Polysaccharide Vaccine and a Decade after the Advent of Conjugates. Clin. Microbiol. Rev. 2000, 13, 302–317, doi:10.1128/CMR.13.2.302.

4. World Health Organization; others Immunological Basis for Immunization: Haemophilus Influenzae type b Vaccines. 2007.

5. World Health Organization Haemophilus influenzae type b (Hib) Vaccination Position Paper – July 2013. Releve Epidemiol. Hebd. 2013, 88, 413–426.

6. Slack MPE, Cripps AW, Grimwood K, et al. Invasive Haemophilus influenzae Infections after 3 Decades of Hib Protein Conjugate Vaccine Use. Clin. Microbiol. Rev. 2021. Vol. 34, № 3. P. e00028-21.

7. Dhillon S. DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa): A Review of its Use as Primary and Booster Vaccination. Drugs. 2010 May 28;70(8):1021-58. DOI: 10.1128/CMR.00028-21.

8. Kalies, H.; Verstraeten, T.; Grote, V, et al; Erhebungseinheit für seltene pädiatrische Erkrankungen in Deutschland Study Group Four and One-Half-Year Follow-up of the Effectiveness of Diphtheria-Tetanus Toxoids-Acellular Pertussis/Haemophilus Influenzae Type b and Diphtheria-Tetanus Toxoids-Acellular Pertussis-Inactivated Poliovirus/H. Influenzae Type b Combination Vaccines in Germany. Pediatr. Infect. Dis. J. 2004, 23, 944–950, doi:10.1097/01.inf.0000141743.74443.73.

9. World Health Organization, others. Haemophilus influenzae type b (Hib) meningitis in the pre-vaccine era: a global review of incidence, age distributions, and case-fatality rates. World Health Organization, 2002.

10. Park JJ, NarayananS, Tiefenbach J., et al. Estimating the global and regional burden of meningitis in children caused by Haemophilus influenzae type b: A systematic review and meta-analysis. Доступно на: https://jogh.org/2022/jogh-12-0407.

11. Slack M P E, Cripps A W, Grimwood K, et al.. Invasive Haemophilus influenzae Infections after 3 Decades of Hib Protein Conjugate Vaccine Use. Clin Microbiol Rev. 2021 Jun 2;34(3):e00028-21. doi: 10.1128/CMR.000289.

12. WHO Global immunization covererage 2023. Доступно на: //www.who.int/news-room/fact-sheets/detail/immunization-cover2.

13. Watt JP, Wolfson LJ, O’Brien KL, et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimat. Lancet Lond. Engl. 2009. Vol. 374, № 9693. P. 903–911.

14. Surveillance report. Haemophilus influenzae disease. Annual Epidemiological Report for 2022.

15. Ulanova M. Global Epidemiology of Invasive Haemophilus influenzae type a Disease: Do We Need a New Vaccine? Journal of Vaccines. 2013. Vol. 2013, № 1. P. 941461.

16. Kalangi H, Ajit AA, Camins B, Yancovitz SR. Haemophilus influenzae serotype a meningitis in an elderly patient: A case report and literature review. IDCases. 2024. Vol. 38. P. e02094.

17. Wenger J.D. Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada. Pediatr. Infect. Dis. J. 1998. Vol. 17, № 9 Suppl. P. S132-136.

18. Coulehan JL, Michaels RH, Hallowell C, et al. Epidemiology of Haemophilus influenzae type B disease among Navajo India. Public Health Rep. Wash. DC 1974. 1984. Vol. 99, № 4. P. 404–409.

19. Bulkow LR, Wainwright RB, Letson GW, et al. Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska Native infants. Pediatr. Infect. Dis. J. 1993. Vol. 12, № 6. P. 484–492.

20. Soeters HM, Blain A, Pondo T, et al. Current Epidemiology and Trends in Invasive Haemophilus influenzae Disease-United States, 2009-2015. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2018. Vol. 67, № 6. P. 881–889.

21. MacNeil JR, Cohn AC, Farley M, et al. Current epidemiology and trends in invasive Haemophilus influenzae disease--United States, 1989-2008. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2011. Vol. 53, № 12. P. 1230–1236.

22. Ulanova M, Tsang RS, Goldfarb DM, et al. Prevalence of Haemophilus influenzae in the nasopharynx of children from regions with varying incidence of invasive H. influenzae serotype a disease: Canadian Immunization Research Network (CIRN) study. Int J Circumpolar Health. 2024;83(1):2371111.

23. Garcia S, Lagos R, Muñoz A, et al. Impact of vaccination against Haemophilus influenzae type b with and without a booster dose on meningitis in four South American countri. Vaccine. 2012. Vol. 30, № 2. P. 486–492.

24. Tohme RA, Francois J, Cavallaro KF, et al. Expansion of Vaccination Services and Strengthening Vaccine-Preventable Diseases Surveillance in Haiti, 2010-2016. Am. J. Trop. Med. Hyg. 2017. Vol. 97, № 4_Suppl. P. 28–36.

25. Tuyama M, Corrêa-Antônio J, Schlackman J, et al. Invasive Haemophilus influenzae disease in the vaccine era in Rio de Janeiro, Brazil. Mem. Inst. Oswaldo Cruz. 2017. Vol. 112, № 3. P. 196–202.

26. Rodriguez RS, Mascarenas C, Conde-Glez CJ, et al. Serological protection induced by Haemophilus influenzae Type B conjugate vaccine in Mexican children: is a booster dose of the vaccine needed.Clin. Vaccine Immunol. CVI. 2010. Vol. 17, № 10. P. 1639–1641.

27. León ME, Kawabata A, Nagai M, et al. Epidemiologic study of Haemophilus influenzae causing invasive and non-invasive disease in Paraguay (1999-2017). Enfermedades Infecc. Microbiol. Clin. Engl. Ed. 2021. Vol. 39, № 2. P. 59–64.

28. Tsang RSW, Ulanova M. The changing epidemiology of invasive Haemophilus influenzae disease: Emergence and global presence of serotype a strains that may require a new vaccine for control. Vaccine. 2017. Vol. 35, № 33. P. 4270–4275.

29. Ribeiro GS, Reis JN, Cordeiro SM, et al. Prevention of Haemophilus influenzae type b (Hib) meningitis and emergence of serotype replacement with type a strains after introduction of Hib immunization in Brazil. J. Infect. Dis. 2003. Vol. 187, № 1. P. 109–116.

30. Zanella RC, Bokermann S, Galhardo M, et al. Trends in serotype distribution and antimicrobial susceptibility pattern of invasive Haemophilus influenzae isolates from Brazil, 2009-2021. Int Microbiol. 2025 Jan;28(1):157-163. doi: 10.1007/s10123-024-00535-5. Epub 2024 May 15. PMID: 38748296

31. Hausdorff WP, Hajjeh R, Al-Mazrou A, et al. The epidemiology of pneumococcal, meningococcal, and Haemophilus disease in the Middle East and North Africa (MENA) region--current status and nee. Vaccine. 2007. Vol. 25, № 11. P. 1935–1944.

32. Youssef FG, El-Sakka H, Azab A, et al. Etiology, antimicrobial susceptibility profiles, and mortality associated with bacterial meningitis among children in Egypt. Ann. Epidemiol. 2004. Vol. 14, № 1. P. 44–48.

33. van Ettekoven CN, Liechti FD, Brouwer MC, et al. Global Case Fatality of Bacterial Meningitis During an 80-Year Period: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2024 Aug 1;7(8):e2424802. doi: 10.1001/jamanetworkopen.2024.24802. PMID: 39093565; PMCID: PMC11297475.

34. Elsaid MF, Alsoub H, Bessisso MS, et al. Clinical presentation of acute bacterial meningitis in Qatar. Neurosci. Riyadh Saudi Arab. 2002. Vol. 7, № 4. P. 266–271.

35. Zaidi AK, Khan H, Sherali AR, et al. Burden of Haemophilus influenzae type b disease in Pakistani children. East. Mediterr. Health J. Rev. Sante Mediterr. Orient. 2010. Vol. 16, № 6. P. 590–594.

36. Al-Mazrou YY, Al-Jeffri MH, Al-Haggar H, et al. Haemophilus type B meningitis in Saudi children under 5 years old.J. Trop. Pediatr. 2004. Vol. 50, № 3. P. 131–136.

37. von Gottberg A, Cohen C, Whitelaw A, et al. Invasive disease due to Haemophilus influenzae serotype b ten years after routine vaccination, South Africa, 2003-2009. Vaccine. 2012. Vol. 30, № 3. P. 565–571.

38. National Institute for Communicable Diseases. GERMS South Africa: annual surveillance review. 2018.

39. Mwenda JM, Soda E, Weldegebriel G, et al. Pediatric Bacterial Meningitis Surveillance in the World Health Organization African Region Using the Invasive Bacterial Vaccine-Preventable Disease Surveillance Network, 2011.Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2019. Vol. 69, Suppl 2. P. S49–S57.

40. Boni-Cisse C, Jarju S, Bancroft RE, et al. Etiology of Bacterial Meningitis Among Children <5 Years Old in Côte d’Ivoire: Findings of Hospital-based Surveillance Before and After Pneumococcal Conjugate Vaccine Introducti. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2019. Vol. 69, № Suppl 2. P. S114–S120.

41. Ndiaye D, Diatta G, Bassene H, et al. Prevalence of Respiratory Pathogens in Nasopharyngeal Swabs of Febrile Patients with or without Respiratory Symptoms in the Niakhar Area of Rural Senegal. Pathogens. 2024;13(8):65.

42. Miller M.A. An assessment of the value of Haemophilus influenzae type b conjugate vaccine in As.// Pediatr. Infect. Dis. J. 1998. Vol. 17, № 9 Suppl. P. S152-159.

43. Invasive Bacterial Infections Surveillance (IBIS) Group of the International Clinical Epidemiology Network. Are Haemophilus influenzae infections a significant problem in India? A prospective study and revi. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2002. Vol. 34, № 7. P. 949–957.

44. Rerks-Ngarm S, Treleaven SC, Chunsuttiwat S, et al. Prospective population-based incidence of Haemophilus influenzae type b meningitis in Thailand. Vaccine. 2004. Vol. 22, № 8. P. 975–983.

45. Ramachandran P, Fitzwater SP, Aneja S, et al. Prospective multi-centre sentinel surveillance for Haemophilus influenzae type b & other bacterial meningitis in Indian children. Indian J Med Res. 2013 Apr;137(4):712-20. PMID: 23703338; PMCID: PMC3724251.

46. Rajkumar P, Bharathy S, Girish Kumar CP, et al. Hospital-based sentinel surveillance for Streptococcus pneumoniae and other invasive bacterial diseases in India (HBSSPIBD): design and methodolo. BMJ Open. 2020. Vol. 10, № 4. P. e034663.

47. Gessner BD, Sutanto A, Linehan M, et al. Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamletrandomised vaccine-probe trial. Lancet Lond. Engl. 2005. Vol. 365, № 9453. P. 43–52.

48. Baqui AH, El Arifeen S, Saha SK, et al. Effectiveness of Haemophilus influenzae type B conjugate vaccine on prevention of pneumonia and meningitis in Bangladeshi children: a case-control study. Pediatr. Infect. Dis. J. 2007. Vol. 26, № 7. P. 565–571.

49. Krisna MA, Alimsardjono L, Salsabila K, et al. Whole-genome sequencing of non-typeable Haemophilus influenzae isolated from a tertiary care hospital in Surabaya, Indonesia [published correction appears in BMC. Infect Dis. 2024 Nov 21;24(1):1326.

50. Yang Y, Yang Y, Scherpbier RW, et al. Coverage of Haemophilus influenzae Type b Conjugate Vaccine for Children in Mainland China: Systematic Review and Meta-analys. Pediatr. Infect. Dis. J. 2019. Vol. 38, № 3. P. 248–252.

51. NNDSS Annual Report Writing Group, et al. Australia’s notifiable disease status, 2010: annual report of the National Notifiable Diseases Surveillance System. Commun. Dis. Intell. Q. Rep. 2012. Vol. 36, № 1. P. 1–69.

52. Maguire JE, Beard F, MéderK, et al. Australian vaccine preventable disease epidemiological review series: invasive Haemophilus influenzae type b disease, 2000–2017. Commun. Dis. Intell. 2018. 2020. Vol. 44.

53. Walls T, Cho V, Martin N, et al. Vaccine Impact on Long-term Trends in Invasive Bacterial Disease in New Zealand Children. Pediatr. Infect. Dis. J. 2018. Vol. 37, № 10. P. 1041–1047.

54. Suga S, Ishiwada N, Sasaki Y, et a. A nationwide population-based surveillance of invasive Haemophilus influenzae diseases in children after the introduction of the Haemophilus influenzae type b vaccine in Japan. Vaccine. 2018. Vol. 36, № 38. P. 5678–5684.

55. Naito S, Takeuchi N, Ohkusu M, et al. Clinical and Bacteriologic Analysis of Nontypeable Haemophilus influenzae Strains Isolated from Children with Invasive Diseases in Japan from 2008 to 2015. J. Clin. Microbiol. 2018. Vol. 56, № 7. P. e00141-18.

56. European Centre for Disease Prevention and Control. Haemophilus influenza –Annual Epidemiological Report for 2018–2020. Доступно: на https://www.ecdc.europa.eu/en/publications-data/haemophilus-influenzae-annual-epidemiological-report-2018 (accessed: 20.05.2024).

57. Ladhani S.N. Two decades of experience with the Haemophilus influenzae serotype b conjugate vaccine in the United Kingdom. Clin. Ther. 2012. Vol. 34, № 2. P. 385–399.

58. Ladhani S.N., Ramsay M., Slack M.P.E. The impact of Haemophilus influenzae serotype B resurgence on the epidemiology of childhood invasive Haemophilus influenzae disease in England and Wales. Pediatr. Infect. Dis. J. 2011. Vol. 30, № 10. P. 893–895.

59. Takla A, Schönfeld V, Claus H, et al. Invasive Haemophilus influenzae Infections in Germany After the Introduction of Routine Childhood Immunization, 201–2016. Open Forum Infect. Dis. 2020. Vol. 7, № 10. P. ofaa444.

60. Heliodoro CIM, Bettencourt CR, Bajanca-Lavado MP. Molecular epidemiology of invasive Haemophilus influenzae disease in Portugal: an update of the post-vaccine period, 2011–2018. Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol. 2020. Vol. 39, № 8. P. 1471–1480.

61. Kojouharova M, Gatcheva N, Setchanova L, et al. Epidemiology of meningitis due to Haemophilus influenzae type b in children in Bulgaria: a prospective, population-based surveillance study. Bull. World Health Organ. 2002. Vol. 80, № 9. P. 690–695.

62. Griffiths UK, Clark A, Shimanovich V, et al. Comparative economic evaluation of Haemophilus influenzae type b vaccination in Belarus and Uzbekist. PloS One. 2011. Vol. 6, № 6. P. e21472.

63. Королва М. А., Гриай М. И., Чурилова Н. С. и др. Эпидемиологические особенности гнойного бактериального менингита в Российской Федерации на современном этапе. Эпидемиологя и Вакцинопрофилактика. 2023;22 (4):67–74.

64. Эпидемиология и вакцинопрофилактика инфекции, вызываемой Haemophilus influenzae типа b. Методические рекомендации. МР 3.3.1.0001-10 (утв. Роспотребнадзором 31.03.2010).

65. Platonov AE, Griffiths UK, Voeykova MV, et al. Economic evaluation of Haemophilus influenzae type b vaccination in Moscow, Russian Federatine. Vaccine, 2006. Vol. 24, № 13.

66. Приказ Минздрава РФ от 06.12.2021 N 1122Н – Редакция от 06.12.2021 – Контур. Доступно на https://normativ.kontur.ru/document?moduleId=1&documentId=410331.

67. О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2023 году: Государственный доклад. Москва:Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2024. – 364 с. ISBN 978–5–7508–2132–7.

68. Brueggemann AB, Jansen van Rensburg MJ, Shaw D, et al. Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. Lancet Digit. Health. 2021. Vol. 3, № 6. P. e360–e370.

69. Грицай М. И., Королева И. С., Королева М. А. Гемофильный менингит – современные аспекты эпидемиологии и профилактики: описательный обзор. Эпидемиология и Вакцинопрофилактика. 2024;22(6):162–174.

70. Ladhani SN, Collins S, Vickers A, et al. Invasive Haemophilus influenzae serotype e and f disease, England and Wales. Emerg. Infect. Dis. 2012. Vol. 18, № 5. P. 725–732.

71. Van Eldere J, Slack MP, Ladhani S, et al. Non-typeable Haemophilus influenzae, an under-recognised pathogen. Lancet Infect. Dis. 2014. Vol. 14, № 12. P. 1281–1292.

72. Collins S, Vickers A, Ladhani SN, et al. Clinical and Molecular Epidemiology of Childhood Invasive Nontypeable Haemophilus influenzae Disease in England and Wales. Pediatr. Infect. Dis. J. 2016. Vol. 35, № 3. P. e76-84.

73. Овенко Н. Н., Ястребова Н. Е. Антигены поверхностных структур Haemophilus influenzae как перспективные кандидат-вакцины. Журнал микробиологии, эпидемиологии и иммунобиологии. 2017.2017, № 4, С. 82–90.